Interaction of CYP2B6 Genotype and Efavirenz With Methadone and Tizanidine PK

Recruiting Early Phase 1 Interventional Study
Drug-Drug Interaction
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Healthy Volunteers Welcome You do not need to have the condition being studied to take part.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 65
Sex
Any
Trial phase
Early Phase 1
Study type
Interventional
Purpose
Basic Science
Participants needed
60 (estimated)
Sponsor
Indiana University · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
The main goal of this clinical study is to test how CYP2B6 genetic variations and efavirenz (cornerstone in HIV-1 therapy) dictate the disposition (PK) of CYP2B6 substrate (methadone) and PK and effect (PD) of CYP1A2 substrate (tizanidine). Specifically, the investigators will test whether efavirenz produces CYP2B6 genotype dependent unanticipated DDIs with CYP2B6 (methadone) and CYP1A2 (tizanidin…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: Subjects will be included in the study if participants: * are male and female (approximately 1:1) volunteers between the age of 18 and 65 years old * are judged healthy without any significant medical condition as determined by and decided from a pre-enrollment screening sessio…
Contacts

Zeruesenay Desta, PhD

3172742823

zdesta@iu.edu

CONTACT

Abi Colwell

317-274-2715

abcolwel@iu.edu

CONTACT